Movement Tracking Devices to Monitor Physical Activity in Patients Undergoing Chemotherapy
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 60
Summary
- Conditions
- Solid Neoplasm
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Other
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: I. To determine the feasibility of monitoring cancer patients using wrist-worn activity monitors and movement trackers. SECONDARY OBJECTIVES: I. To evaluate the association between activity and patient reported fatigue. II. To evaluate the association between movement and inciden...
PRIMARY OBJECTIVES: I. To determine the feasibility of monitoring cancer patients using wrist-worn activity monitors and movement trackers. SECONDARY OBJECTIVES: I. To evaluate the association between activity and patient reported fatigue. II. To evaluate the association between movement and incidents of health care interventions (hospitalizations, physical visits, intravenous hydration, etc.) TERTIARY OBJECTIVES: I. To compare physician and patient assessed Eastern Cooperative Oncology Group (ECOG) and Karnofsky performance status scores with the data obtained from movement trackers. OUTLINE: Patients perform 2 physical activities in an exam room that are recorded using a Microsoft Kinect 2 stationary movement tracking device on days 1 and 21. The first activity is rising from a chair, walking 10 feet, and returning to the chair. The second activity is moving from the chair to the step-up examination table. Patients also wear a movement tracking wristband, Microsoft Band 2, around their wrist, complete a smartphone application based patient reported outcome (PRO) questionnaire, and weigh themselves daily for 60 days. After completion of study, patients are followed up at 90 days.
Tracking Information
- NCT #
- NCT03098277
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Jorge Nieva University of Southern California